|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DAP |
Gene summary for DAP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DAP | Gene ID | 1611 |
| Gene name | death associated protein | |
| Gene Alias | DAP | |
| Cytomap | 5p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DQ75 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1611 | DAP | HTA11_1938_2000001011 | Human | Colorectum | AD | 6.63e-04 | 4.68e-01 | -0.0811 |
| 1611 | DAP | HTA11_78_2000001011 | Human | Colorectum | AD | 4.65e-02 | 4.43e-01 | -0.1088 |
| 1611 | DAP | HTA11_347_2000001011 | Human | Colorectum | AD | 6.08e-10 | 4.85e-01 | -0.1954 |
| 1611 | DAP | HTA11_411_2000001011 | Human | Colorectum | SER | 2.17e-04 | 1.04e+00 | -0.2602 |
| 1611 | DAP | HTA11_696_2000001011 | Human | Colorectum | AD | 3.14e-09 | 5.69e-01 | -0.1464 |
| 1611 | DAP | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.60e-10 | 6.78e-01 | -0.059 |
| 1611 | DAP | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.29e-02 | 4.87e-01 | 0.0588 |
| 1611 | DAP | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.20e-02 | 5.68e-01 | 0.3859 |
| 1611 | DAP | A015-C-203 | Human | Colorectum | FAP | 1.36e-21 | -3.63e-01 | -0.1294 |
| 1611 | DAP | A015-C-204 | Human | Colorectum | FAP | 2.43e-02 | -1.60e-01 | -0.0228 |
| 1611 | DAP | A002-C-201 | Human | Colorectum | FAP | 2.02e-07 | -2.83e-01 | 0.0324 |
| 1611 | DAP | A002-C-203 | Human | Colorectum | FAP | 2.61e-05 | -1.44e-01 | 0.2786 |
| 1611 | DAP | A001-C-119 | Human | Colorectum | FAP | 4.00e-03 | -2.73e-01 | -0.1557 |
| 1611 | DAP | A001-C-108 | Human | Colorectum | FAP | 1.29e-12 | -2.62e-01 | -0.0272 |
| 1611 | DAP | A002-C-205 | Human | Colorectum | FAP | 5.28e-11 | -2.68e-01 | -0.1236 |
| 1611 | DAP | A015-C-006 | Human | Colorectum | FAP | 3.56e-08 | -3.31e-01 | -0.0994 |
| 1611 | DAP | A015-C-106 | Human | Colorectum | FAP | 1.60e-08 | -2.54e-01 | -0.0511 |
| 1611 | DAP | A002-C-114 | Human | Colorectum | FAP | 2.27e-10 | -3.64e-01 | -0.1561 |
| 1611 | DAP | A015-C-104 | Human | Colorectum | FAP | 6.12e-20 | -3.78e-01 | -0.1899 |
| 1611 | DAP | A001-C-014 | Human | Colorectum | FAP | 2.06e-11 | -2.16e-01 | 0.0135 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:009753010 | Skin | AK | granulocyte migration | 27/1910 | 148/18723 | 2.01e-03 | 1.35e-02 | 27 |
| GO:000926720 | Skin | AK | cellular response to starvation | 28/1910 | 156/18723 | 2.15e-03 | 1.43e-02 | 28 |
| GO:00716226 | Skin | AK | regulation of granulocyte chemotaxis | 12/1910 | 51/18723 | 4.45e-03 | 2.58e-02 | 12 |
| GO:004259420 | Skin | AK | response to starvation | 32/1910 | 197/18723 | 5.47e-03 | 3.02e-02 | 32 |
| GO:19026245 | Skin | AK | positive regulation of neutrophil migration | 8/1910 | 28/18723 | 5.55e-03 | 3.05e-02 | 8 |
| GO:19902668 | Skin | AK | neutrophil migration | 22/1910 | 122/18723 | 5.74e-03 | 3.13e-02 | 22 |
| GO:00900236 | Skin | AK | positive regulation of neutrophil chemotaxis | 7/1910 | 24/18723 | 8.26e-03 | 4.13e-02 | 7 |
| GO:2001233112 | Skin | SCCIS | regulation of apoptotic signaling pathway | 51/919 | 356/18723 | 5.51e-12 | 7.43e-09 | 51 |
| GO:0097193112 | Skin | SCCIS | intrinsic apoptotic signaling pathway | 42/919 | 288/18723 | 2.40e-10 | 2.12e-07 | 42 |
| GO:003210315 | Skin | SCCIS | positive regulation of response to external stimulus | 51/919 | 427/18723 | 3.99e-09 | 1.76e-06 | 51 |
| GO:2001242112 | Skin | SCCIS | regulation of intrinsic apoptotic signaling pathway | 28/919 | 164/18723 | 7.32e-09 | 2.95e-06 | 28 |
| GO:003059515 | Skin | SCCIS | leukocyte chemotaxis | 33/919 | 230/18723 | 3.03e-08 | 7.00e-06 | 33 |
| GO:007162115 | Skin | SCCIS | granulocyte chemotaxis | 23/919 | 125/18723 | 3.79e-08 | 7.72e-06 | 23 |
| GO:005092012 | Skin | SCCIS | regulation of chemotaxis | 32/919 | 223/18723 | 4.88e-08 | 8.19e-06 | 32 |
| GO:005090016 | Skin | SCCIS | leukocyte migration | 44/919 | 369/18723 | 4.93e-08 | 8.19e-06 | 44 |
| GO:006032615 | Skin | SCCIS | cell chemotaxis | 39/919 | 310/18723 | 6.84e-08 | 1.04e-05 | 39 |
| GO:009752916 | Skin | SCCIS | myeloid leukocyte migration | 31/919 | 220/18723 | 1.20e-07 | 1.52e-05 | 31 |
| GO:009753013 | Skin | SCCIS | granulocyte migration | 24/919 | 148/18723 | 2.33e-07 | 2.38e-05 | 24 |
| GO:005092114 | Skin | SCCIS | positive regulation of chemotaxis | 23/919 | 141/18723 | 3.72e-07 | 3.23e-05 | 23 |
| GO:000268517 | Skin | SCCIS | regulation of leukocyte migration | 29/919 | 210/18723 | 4.69e-07 | 3.77e-05 | 29 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DAP | SNV | Missense_Mutation | c.235G>C | p.Glu79Gln | p.E79Q | protein_coding | deleterious_low_confidence(0.02) | benign(0.015) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| DAP | SNV | Missense_Mutation | rs753757154 | c.278N>C | p.His93Pro | p.H93P | protein_coding | deleterious_low_confidence(0) | benign(0.01) | TCGA-E2-A1L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| DAP | SNV | Missense_Mutation | rs77265616 | c.173G>A | p.Arg58Gln | p.R58Q | protein_coding | tolerated_low_confidence(0.08) | benign(0.029) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
| DAP | SNV | Missense_Mutation | rs759102630 | c.127N>A | p.Asp43Asn | p.D43N | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.984) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| DAP | SNV | Missense_Mutation | novel | c.167C>T | p.Ser56Phe | p.S56F | protein_coding | deleterious_low_confidence(0) | benign(0.036) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DAP | SNV | Missense_Mutation | c.74G>A | p.Arg25Gln | p.R25Q | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.643) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| DAP | SNV | Missense_Mutation | novel | c.373C>A | p.Leu125Ile | p.L125I | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.534) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| DAP | SNV | Missense_Mutation | novel | c.391N>T | p.Leu131Phe | p.L131F | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DAP | SNV | Missense_Mutation | rs753757154 | c.278N>C | p.His93Pro | p.H93P | protein_coding | deleterious_low_confidence(0) | benign(0.01) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| DAP | SNV | Missense_Mutation | rs370396587 | c.182G>A | p.Arg61His | p.R61H | protein_coding | tolerated_low_confidence(0.16) | benign(0.009) | TCGA-D1-A17U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |